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Abstract (Pro)renin receptor-bound prorenin not only
causes the generation of angiotensin II via the nonproteo-
lytic activation of prorenin, it also activates the receptor’s
own intracellular signaling pathways independent of the
generated angiotensin II. Within the kidneys, the (pro)renin
receptor is not only present in the glomerular mesangium, it
is also abundant in podocytes, which play an important role
in the maintenance of the glomerular filtration barrier. Recent
in vivo studies have demonstrated that the overexpression of
the (pro)renin receptor to a degree similar to that observed
in hypertensive rat kidneys leads to slowly progressive
nephropathy with proteinuria. In addition, the handle region
peptide, which acts as a decoy peptide and competitively
inhibits the binding of prorenin to the receptor, is more
beneficial than an angiotensin-converting enzyme inhibitor
with regard to alleviating proteinuria and glomerulosclerosis
in experimental animal models of diabetes and essential
hypertension. Thus, the (pro)renin receptor may be upregu-
lated in podocytes under hypertensive conditions and may
contribute to the breakdown of the glomerular filtration
barrier.
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Introduction
When the (pro)renin receptor binds to the “handle” region
of inactive prorenin, the receptor-bound prorenin gains its
enzyme activity (ability to generate angiotensin I) without
the proteolytic cleavage of the prosegment of prorenin in
COS-7 cells [1, 2], presumably as a result of a conforma-
tional change. On the other hand, receptor-bound prorenin
also triggers its own intracellular signaling pathways
independent of the generated angiotensin II. Studies have
shown that the stimulation of the (pro)renin receptor by
renin/prorenin activates tyrosine phosphorylation leading to
the activation of extracellular signal-related protein kinases
(ERK) [3] and upregulates transforming growth factor-β1
(TGF-β1) and matrix proteins without involving angioten-
sin II generation in human and rat mesangial cells [4]. In
this review, we focus on the latest progress in elucidating
the localization, regulation, and pathophysiological roles of
the (pro)renin receptor in the kidneys.
Localization in the kidney
Studies have demonstrated that the (pro)renin receptor
protein and messenger ribonucleic acid (mRNA) are
expressed in the mesangium cells of human kidneys [3,
4]. However, double immunohistochemical analyses using
a polyclonal antirat (pro)renin receptor antibody demon-
strated that the (pro)renin receptor was colocalized with a
podocyte marker, podocalyxin, but not with a mesangium
marker, Thy1.1, in rat kidneys [5] and electron microscopic
analyses appeared to indicate the predominant presence of
the rat (pro)renin receptor in podocytes, excluding the foot
processes, and its absence in mesangial cells [5]. In
addition, we recently detected (pro)renin receptor mRNA
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glomerulus, podocytes play an important role in the mainte-
nance of the glomerular filtration barrier and podocyte injury
leads to proteinuria and initiates glomerulosclerosis resulting
in the progressive loss of renal function [6]. Therefore, (pro)
renin receptor in the podocytes may contribute to proteinuria
and renal injury through an angiotensin-II-dependent path-
way, an angiotensin-II-independent pathway, or both path-
ways in chronic kidney diseases.
Possible upregulation of (pro)renin receptor expression
under hypertensive conditions
In the kidneys of young hypertensive stroke-prone sponta-
neously hypertensive rats (SHRsp), an increase by two- or
threefold in the mRNA expression of the (pro)renin
receptor has been observed [7]. However, the kidneys of
older hypertensive SHRsp did not show an elevation in
(pro)renin receptor mRNA expression. Because the binding
of renin to the (pro)renin receptor lowers the (pro)renin
receptor mRNA level through a promyelocytic zinc-finger-
protein-mediated negative feedback mechanism [8], a
further increase in the plasma renin levels in old hyperten-
sive SHRsp might inhibit the increase in (pro)renin receptor
mRNA levels through a negative feedback loop. More
recently, enhanced mRNA expression of the (pro)renin re-
ceptor was also observed in the clipped kidneys of Goldblatt
hypertensive rats [9]. These results seem to provide evidence
of the importance of hypertensive conditions in the regula-
tion of (pro)renin receptor expression in the kidneys.
Effects of (pro)renin receptor overexpression
on the kidney
Recent studies in transgenic rats overexpressing the human
(pro)renin receptor gene nonspecifically by three to seven
times demonstrated that glomerulosclerosis with proteinuria
developed at 5–6months of age even in the absence of an
elevation in blood pressure [10]. In the kidneys of 5- to 6-
month-old transgenic rats, mitogen-activated protein kinase
(s) (MAPK(s)) were activated without recognizable tyrosine
phosphorylation of the epidermal growth factor receptor
and the expression of TGF-β1 was enhanced. The in vivo
administration of angiotensin-converting enzyme (ACE)
inhibitor did not inhibit the development of glomeruloscle-
rosis, proteinuria, MAPK activation, or TGF-β1 expression
in the kidneys despite a significant decrease in the renal
angiotensin II level. As shown in Fig. 1, recombinant rat
prorenin stimulated MAPK activation in human-receptor-
expressed cultured cells but human receptor was unable to
evoke the enzyme activity of rat prorenin. Thus, the over-
expression of the human (pro)renin receptor elicits slowly
progressive nephropathy via angiotensin-II-independent
MAPK activation but not through the stimulation of angio-
tensin II generation. However, hypertension developed at
7months of age in transgenic rats overexpressing the human
(pro)renin receptor gene exclusively in smooth muscle cells
[11]. Because young transgenic rats of this strain show an
enhanced expression of macula densa cyclooxygenase-2 that
suppresses the tubuloglomerular feedback system and con-
tributes to the inhibition of hypertension development [12],
hypertension may not yet have developed at 6months of age
or earlier. Therefore, we can interpret these observations as
indicating that the hypertension may have occurred as a
result of the nephropathy. However, further studies are
needed to elucidate the involvement of the (pro)renin re-
ceptor in the development of hypertension.
Receptor-bound prorenin in diabetic kidneys
Recombinant prorenin binds to recombinant (pro)renin
receptor expressed compulsorily on the cell surfaces of
COS-7 cells and prorenin bound to the receptor on the cell
surfaces exerts renin activity without undergoing any change
in its molecular weight. However, synthetic peptides con-
taining the amino acid sequence corresponding to the
“handle” region of the prorenin prosegment competitively
inhibit prorenin from binding to cell membrane receptors
[13]. In the absence of experimental data showing the
blockade of renin signaling by the handle region peptide, we
believe that the possible inhibition of receptor signals and
angiotensin II generation by the handle region peptide should
be interpreted as indicating the blockade of prorenin binding.
Diabetic animals or patients have lower renin levels and
higher prorenin levels than normal healthy controls [14,
15]. The handle region peptide was administered to rats
with streptozotosin-induced type I diabetes and the tissue
angiotensin I and II levels in their kidneys, and the
development of nephropathy were followed [16]. The
administration of the handle region peptide for 6months
significantly inhibited the increase in renal angiotensin II
levels and the development of proteinuria and glomerulo-
sclerosis, suggesting that the nonproteolytic activation of
prorenin bound to the (pro)renin receptor plays an
important role in the development of nephropathy. Al-
though renal mRNA expression of the (pro)renin receptor
was similar in the control and diabetic rats [17], non-
proteolytically activated prorenin increased in the kidneys
of the diabetic rats, and this increase was inhibited by the
handle region peptide. In addition, the renal total renin
content remained unchanged during the treatment with the
handle region peptide. These results suggested that the
handle region peptide inhibits the conformational change in
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not alter the prorenin levels. Because the mRNA expression
of cathepsin B, which processes the conversion of prorenin to
renin, simultaneously decreased in the kidneys of the diabetic
rats, prorenin may have accumulated in their kidneys. Also,
the amount of prorenin released to the circulatory system may
be elevated in diabetes leading to an elevation in receptor-
bound prorenin as a result of the increased prorenin levels
with no change in (pro)renin receptor expression.
Toinvestigatethecontributionofangiotensin-II-independent,
(pro)renin-receptor-dependent signal pathways to diabetic
end-organ damage, the therapeutic effects of infusion were
compared with the effect of the deletion of angiotensin II type
1a receptor (ATKO) and ACE inhibition on streptozotosin-
induced type I diabetes [18]. Deletion of the angiotensin II
type 1 gene attenuated the development of glomeruloscle-
rosis and proteinuria but did not prevent these developments.
ACE inhibitor also failed to prevent diabetic nephropathy
despite the normalization ofrenal angiotensin II. On the other
hand, the handle region peptide almost completely prevented
the development of these conditions despite the absence of an
increase in renal angiotensin levels. Of note, MAPKs were
markedly activated in diabetic ATKO animals and, while the
handle region peptide almost completely inhibited the
activation, ACE inhibition failed to even ameliorate it. These
results indicate that inhibition of the angiotensin-II-mediated
pathway had a little therapeutic effect on nephropathy in the
diabeticrats,whereastheblockadeofreceptor-boundprorenin
seemed to suppress the two major pathways for diabetic
nephropathy: excessive production of angiotensin II in the
kidneys and renal MAPK activation. In this experiment, the
renal angiotensin II levels of diabetic mice treated with
the handle region peptide were similar to those of untreated
wild-type mice. Because the handle region peptide did not
seem to inhibit the binding of renin to the (pro)renin receptor,
the physiological production of renal angiotensin II induced
by renin or receptor-bound renin was probably unaffected by
the handle-region-peptide-induced inhibition of receptor-
bound prorenin. In addition, the handle region peptide did
not influence the plasma levels of renin and prorenin
(receptor-unbound free renin and receptor-unbound free
prorenin) or blood pressure. Thus, the handle region peptide
also had no effect on the physiology of the circulating renin–
angiotensin system.
We recently found that the handle region peptide also
leads to the regression of nephropathy in rats with
streptozotosin-induced type I diabetes [17]. Diabetes was
induced by streptozotosin injection in 4-week-old rats.
Increased urinary protein excretion and glomerulosclerosis
were observed 12weeks later and the administration of the
handle region peptide or vehicle was started. While urinary
protein excretion and glomerulosclerosis had progressed in
vehicle-treated 28-week-old diabetic rats, treatment with the
handle region peptide significantly reduced the proteinuria
and glomerulosclerosis from the levels observed at the start
of treatment. This reversal of the glomerulosclerosis that
had already developed in the diabetic rats suggested that
receptor-bound prorenin contributes not only to the onset of
nephropathy but also to its progression.
The increased plasma prorenin level might be supplied
by the kidneys in which high glucose levels might inhibit
the processing of prorenin to renin as described above. In
addition, extrarenal tissues might also be sources of the
increased prorenin level under high glucose conditions
because plasma prorenin is detectable even after a bilateral
nephrectomy [15]. Thus, high glucose levels may contrib-
ute to an increase in the plasma prorenin level via both
renal and extrarenal mechanisms, and the elevated plasma
prorenin level might trigger an increase in receptor-bound
prorenin leading to nephropathy. These mechanisms may
explain why the handle region peptide inhibited the
development and progression of nephropathy in animal
models of diabetes without affecting the high blood glucose
level. Further study is needed to clarify these points.
Angiotensinogen
Angiotensin I
Human
prorenin
Human prorenin prosegment
MAPK pathways
h(P)RR
Angiotensinogen
Rat
prorenin
Rat prorenin prosegment
MAPK pathways
h(P)RR
Cell membrane
Fig. 1 Both rat and human
prorenin stimulate human
(pro)renin receptor (h(P)RR)-
dependent intracellular signals,
but the h(P)RR activates human
prorenin but does not activate
rat prorenin
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SHRsp rats have high plasma levels of prorenin and renin
and are used as a model of primary hypertension [19]. In
addition to the increased mRNA expression of the (pro)
renin receptor as described above, elevated angiotensin I
and II levels and glomerulosclerosis with proteinuria have
been observed in the kidneys of young hypertensive
SHRsp; administration of the handle region peptide
significantly suppressed these changes without affecting
the development of hypertension [7]. In addition, profi-
brotic changes in morphology were observed in the clipped
kidneys of Goldblatt hypertensive rats with enhanced
mRNA expression of the (pro)renin receptor [9]. Therefore,
the increased expression of the (pro)renin receptor may play
an important role in the development of renal tissues
showing characteristic signs of hypertensive damage.
Because recent studies have demonstrated the presence of
angiotensin-II-independent, (pro)renin-receptor-dependent
MAPK pathways in mesangial cells [20] and vascular
smooth muscle cells [21], the beneficial effects of the
handle region peptide may be mediated by both of these
two major pathways that are stimulated by receptor-bound
prorenin. Thus, receptor-bound prorenin also contributes to
the development of hypertensive end-organ damage. This
was recently supported, in part, by Susic et al., who reported
that the handle region peptide significantly reduced the left
ventricular mass even though the myocardial collagen
content remained unchanged [22].
Possible inhibition of receptor-bound prorenin by high
levels of renin
Figure 2 shows the binding of renin and prorenin to the
(pro)renin receptor. Because both renin and prorenin bind
to the (pro)renin receptor [3], increased renin levels may
increase the amount of renin and decrease the amount of
prorenin that binds to the receptor. A recent review reported
that the handle region peptide offered no benefit to renin-
transgenic models or to a model with renovascular hyper-
tension [23]. Because the ratio of renin to prorenin must be
higher in these models than in control models, renin—but
not prorenin—that has bound to the receptor must contrib-
ute to the pathogenesis that occurs in these models. Because
no data showed the blockade of renin signaling by the
handle region peptide, the handle region peptide did not
benefit the renin-transgenic models or the model with
renovascular hypertension [23]. In contrast, the handle
region peptide greatly benefited diabetic animals [16–18].
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Fig. 2 Renin and prorenin competitively bind to the (pro)renin receptor in vivo and to the (pro)renin receptor expressed on the cell surfaces of
COS-7 cells
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of renin to prorenin [15], they have increased levels of
prorenin bound to the receptor and decreased levels of renin
bound to the receptor. Thus, the handle region peptide was
thought to benefit in vivo diabetic animals by reducing the
amount of prorenin that bound to the receptor. In addition,
the handle region peptide had a partial benefit on SHRsp [7,
24] and SHR [22] animals fed a high-salt diet. This benefit
was reduced by changing from a high-salt diet to a low-salt
diet (unpublished preliminary data), suggesting that dietary
salt might alter the levels of prorenin bound to the receptor
by regulating the renin levels. Thus, the efficiency of the
handle region peptide may depend on the ratio of renin to
prorenin.
(Pro)renin receptors in cultured cells
Using vascular smooth muscle cells (VSMC) harvested
from human-(pro)renin-receptor-transgenic rats, Batenburg
et al. recently demonstrated that prorenin binds to the (pro)
renin receptor and that receptor-bound prorenin exerts a
catalytic activity but that renin does not bind to the receptor
or increase its own catalytic activity [25], consistent with
the results of a previous study using human VSMC [21].
The structural difference between renin and prorenin arises
from 43 amino acids in the prorenin prosegment and
prorenin acquires its catalytic activity without changing its
molecular weight when a specific protein binds to the
“handle” region of the prorenin prosegment [1]. Neverthe-
less, the handle region decoy peptide, which inhibited the
binding of prorenin to the receptor in a test tube and to
receptors expressed on the cell surfaces of COS-7 cells
[13], failed to inhibit prorenin’s acquisition of catalytic
activity by binding to the receptor [25]. A recent study
using a human cultured cell line clearly demonstrated that
the 39-kDa full-length (pro)renin receptor was predomi-
nantly present in the intracellular endoplasmic reticulum
[8]. Because both renin and prorenin can permeate the cell
membrane [8] but the handle region peptide cannot, the
handle region peptide might be incapable of inhibiting
intracellular binding between the (pro)renin receptor and its
ligands (Fig. 3).
Although (pro)renin receptors of VSMC harvested from
human-(pro)renin-receptor-transgenic rats were not bound
to renin [25], the same authors also showed that both renin
and prorenin bind to the (pro)renin receptor and stimulate
receptor-dependent ERK pathways in U937 monocytes
[26]. In addition, a renin-stimulated, (pro)renin-receptor-
dependent ERK pathway was observed in rat and human
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(Ref. 27)
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(Ref. 26)
Endoplasmic reticulum
Cultured cells
prorenin
renin
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Fig. 3 Possible fragmentation of (pro)renin receptor in cultured cells
J Mol Med (2008) 86:629–635 633mesangial cells [4, 20], whereas the stimulation of the
receptor by prorenin in cultured cardiomyocytes resulted in
the activation of p-38 MAPK, but not ERK [27], and renin
stimulation caused the interaction between the receptor and
the transcription factor promyelocytic zinc finger protein in
HeLa-S3 cells and HEK293 cells [8]. These results suggest
that the ability to bind renin and prorenin and the intra-
cellular pathways involving these proteins may be influ-
enced by the species and condition of the cultured cells. In
addition, the presence of (pro)renin receptors with molec-
ular weights smaller than the 39kDa of the full-length
receptor in cultured cells has been reported in abstracts
presented at several meetings. Based on the results of all
these studies regarding the (pro)renin receptor in cultured
cells, we propose the possible fragmentation of the (pro)
renin receptor (Fig. 3). Namely, when the 39-kDa full-
length (pro)renin receptor in the endoplasmic reticulum is
released to the cytoplasm, it may divide into a renin-
binding part and a remnant part. In the cytoplasm of VSMC
and cardiomyocytes, the remaining smaller (pro)renin
receptor without the renin-binding part would be capable
of binding prorenin but would be incapable of binding
renin. However, in the cytoplasm of the mesangium and
monocytes, the smaller receptor might readhere to the
renin-binding part and resume its ability to bind renin.
When the smaller receptor in the cytoplasm reaches the cell
membrane, it might further divide into the prorenin-binding
part, recognizing the “handle” region, and a remnant part.
The prorenin-binding part would be released to the
extracellular area and the smallest remnant receptor would
remain at the cell membrane. Because the smallest receptor
does not contain either the renin-binding part or the
prorenin-binding part, it would no longer be capable of
binding renin or prorenin. When the prorenin bound to the
smaller receptor also reaches the cell membrane, it would
divide into three parts: the prorenin prosegment adhered to
the prorenin-binding part, renin, and the remaining smallest
receptor. Because the former two proteins are released
to the extracellular area, angiotensin I generation from
external angiotensinogen would occur there. Thus, under
cultured cell conditions, the (pro)renin receptor may be
fragmented depending on the cell species. Further studies
are needed to verify the possible fragmentation of the (pro)
renin receptor.
Conclusion
In the glomerulus of the kidneys, the (pro)renin receptor is
not only present in the mesangium but is also abundant in
the podocytes and its expression was increased by two- to
threefold in the kidneys of some animal models of hy-
pertension. A transgene-induced overexpression of human
(pro)renin receptor in rats resulted in the development of
slowly progressive nephropathy with proteinuria. In addition,
the handle-region-peptide-induced inhibition of receptor-
bound prorenin significantly inhibited the development and
progression of proteinuria in experimental diabetic and
hypertensive animal models. Thus, the glomerular (pro)renin
receptor appears to play an important role in the regulation of
the glomerular filtration barrier.
Acknowledgements This work was supported in part by grants from
the Ministry of Education, Culture, Sports, Science and Technology of
Japan (16790474 and 17390249), from the Takeda Science Foundation,
and from the Japan Diabetes Foundation. We thank Ms. Miki Chika for
her excellent technical assistance.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Suzuki F, Hayakawa M, Nakagawa T, Nasir UM, Ebihara A,
Iwasawa A, Ishida Y, Nakamura Y, Murakami K (2003) Human
prorenin has “gate and handle” regions for its non-proteolytic
activation. J Biol Chem 278:22217–22222
2. Nabi AHMN, Kageshima A, Uddin M, Nakagawa T, Park E,
Suzuki F (2006) Binding properties of rat prorenin and renin
to the recombinant rat renin/prorenin receptor prepared by a
baculovirus expression system. Int J Mol Med 18:483–488
3. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer J-D
(2002) Pivotal role of the renin/prorenin receptor in angiotensin II
production and cellular responses to renin. J Clin Invest
109:1417–1427
4. Huang Y, Wongamorntham S, Kasting J, McQuillan D, Owens
RT, Yu L, Noble NA, Border W (2006) Renin increases mesangial
cell transforming growth factor-b1 and matrix proteins through
receptor-mediated, angiotensin II-independent mechanisms. Kid-
ney Int 69:105–113
5. Ichihara A, Kaneshiro Y, Takemitsu T, Sakoda M, Itoh H (2007)
The (pro)renin receptor and thekidney.Semin Nephrol 27:524–528
6. Pavenstadt H, Kriz W, Kretzler M (2003) Cell biology of the
glomerular podocyte. Physiol Rev 83:253–307
7. Ichihara A, Kaneshiro Y, Takemitsu T, Sakoda M, Nakagawa T,
Nishiyama A, Kawachi H, Shimizu F, Inagami T (2006)
Contribution of non-proteolytically activated prorenin in glomeruli
to hypertensive renal damage. J Am Soc Nephrol 17:2495–2503
8. Schefe J, Menk M, Reinemund J, Effertz K, Hobbs R, Pandolfi P,
Ruiz P, Unger T, Funke-Kaiser H (2006) A novel signal
transduction cascade involving direct physical interaction of the
renin/prorenin receptor with the transcription factor promyelocytic
zinc finger protein. Circ Res 99:1355–1366
9. Krebs C, Hamming I, Sadaghiani S, Steinmetz OM, Meyer-
Schwesinger C, Fehr S, Stahl RAK, Garrelds IM, Danser AHJ,
Goor, Contrepas A, Nguyen G, Wenzel U (2007) Antihypertensive
therapy upregulates renin and (pro)renin receptor in the clipped
kidney of Goldblatt hypertensive rats. Kidney Int 72:725–730
10. Kaneshiro Y, Ichihara A, Sakoda M, Takemitsu T, Nabi AN,
Uddin MN, Nakagawa T, Nishiyama A, Suzuki F, Inagami T, Itoh H
(2007) Slowly progressive, angiotensin II-independent glomerulo-
sclerosis in human-renin/prorenin-receptor-transgenic rats. J Am Soc
Nephrol 18:1789–1795
634 J Mol Med (2008) 86:629–63511. Burckle CA, Jan Danser AH, Muller DN, Garrelds IM, Gasc JM,
Popova E, Plehm R, Peters J, Bader M, Nguyen G (2006)
Elevated blood pressure and heart rate in human renin receptor
transgenic rats. Hypertension 47:1–5
12. Kaneshiro Y, Ichihara A, Takemitsu T, Sakoda M, Suzuki F,
Nakagawa T, Hayashi M, Inagami T (2006) Increased expression
of cyclooxygenase-2 in renal cortex of human-prorenin-receptor-
gene transgenic rats. Kidney Int 70:641–646
13. Nabi AHMN, Uddin M, Nakagawa T, Iwata H, Ichihara A,
Inagami T, Suzuki F (2007) Role of “handle” region of prorenin
prosegment in the non-proteolytic activation of prorenin by
binding to membrane anchored (pro)renin receptor. Front Biosci
12:4810–4817
14. Hayashi M, Senba S, Saito I, Kitajima W, Saruta T (1983)
Changes in blood pressure, urinary kallikrein, and urinary
prostaglandin E2 in rats with streptozotocin-induced diabetes.
Naunyn Schmiedebergs Arch Pharmacol 322:290–294
15. Derkx F, Schalekamp M (1988) Human prorenin: pathophysiology
and clinical implications. Clin Exp Hypertens A10:1213–1225
16. Ichihara A,Hayashi M,Kaneshiro Y, Suzuki F, NakagawaT, Tada Y,
Koura Y, Nishiyama A, Okada H, Uddin MN, Nabi AHMN,
Ishida Y, Inagami T, Saruta T (2004) Inhibition of diabetic nephro-
pathy by a decoy peptide corresponding to the “handle” region for
non-proteolytic activation of prorenin. J Clin Invest 114:1128–1135
17. Takahashi H, Ichihara A, Kaneshiro Y, Inomata K, Sakoda M,
Takemitsu T, Nishiyama A, Itoh H (2007) Regression of
nephropathydevelopedindiabetesby(pro)reninreceptorblockade.
J Am Soc Nephrol 18:2054–2061
18. Ichihara A, Suzuki F, Nakagawa T, Kaneshiro Y, Takemitsu T,
Sakoda M, Nabi AHMN, Nishiyama A, Sugaya T, Hayashi M,
Inagami T (2006) Prorenin receptor blockade inhibits develop-
ment of glomerulosclerosis in diabetic angiotensin II type 1a
receptor deficient mice. J Am Soc Nephrol 17:1950–1961
19. Obata J, Nakamura T, Takano H, Naito A, Kimura H, Yoshida Y,
Shimizu F, Guo DF, Inagami T (2000) Increased gene expression
of components of the renin-angiotensin system in glomeruli of
genetically hypertensive rats. J Hypertens 18:1247–1255
20. Huang Y, Noble N, Zhang J, Xu C, Border W (2007) Renin-
stimulated TGF-beta1 expression is regulated by a mitogen-
activated protein kinase in mesangial cells. Kidney Int 72:42–52
21. Sakoda M, Ichihara A, Kaneshiro Y, Takemitsu T, Nakazato Y,
Migita T, Nabi AHMN, Nakagawa T, Suzuki F, Inagami T, Itoh H
(2007) (Pro)renin receptor-mediated activation of mitogen-acti-
vated protein kinases in human vascular smooth muscle cells.
Hypertens Res 30:1139–1146
22. Susic D, Lippton H, Knight M, Frohlich ED (2006) Cardiovas-
cular effects of nonproteolytic activation of prorenin. Hyperten-
sion 48:e113
23. Luft FC (2007) Renin and its putative receptor remain enigmas.
J Am Soc Nephrol 18:1989–1992
24. Ichihara A, Kaneshiro Y, Takemitsu T, Sakoda M, Suzuki F,
Nakagawa T, Nishiyama A, Inagami T, Hayashi M (2006) Non-
proteolytic activation of prorenin contributes to development of
cardiac fibrosis in genetic hypertension. Hypertension 47:894–900
25. Batenburg WW, Krop MK, Garrelds IM, deVries R, deBruin RJA,
Burckle CA, Muller DN, Bader M, Nguyen G, Danser AHJ
(2007) Prorenin is the endogenous agonist of the (pro)renin
receptor. Binding kinetics of renin and prorenin in rat vascular
smooth muscle cells overexpressing the human (pro)renin recep-
tor. J Hypertens 25:2441–2453
26. Feldt S, Batenburg WW, Mazak I, Maschke U, Wellner M,
Kvakan H, Dechend R, Fiebeler A, Burckle C, Contrepas A,
Danser AHJ, Bader M, Nguyen G, Luft FC, Muller DN (2008)
Prorenin and renin-induced extracellular signal regulated kinase
1/2 activation in monocytes is not blocked by aliskiren or the
handle-region peptide. Hypertension 51:682–688
27. Saris J, ‘tHoen P, Garrelds I, Dekkers D, denDunnen J, Lamers J,
JanDanser A (2006) Prorenin induces intracellular signaling in
cardiomyocytes independently of angiotensin II. Hypertension
48:564–571
J Mol Med (2008) 86:629–635 635